Rattis Bruna A C, Ramos Simone G, Celes Mara R N
Department of Pathology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
Department of Bioscience and Technology, Institute of Tropical Pathology and Public Health, Federal University of Goias, Goiania, Brazil.
Front Pharmacol. 2021 May 7;12:675287. doi: 10.3389/fphar.2021.675287. eCollection 2021.
Coronavirus disease 2019 (COVID-19) is an infectious disease that rapidly spread throughout the world leading to high mortality rates. Despite the knowledge of previous diseases caused by viruses of the same family, such as MERS and SARS-CoV, management and treatment of patients with COVID-19 is a challenge. One of the best strategies around the world to help combat the COVID-19 has been directed to drug repositioning; however, these drugs are not specific to this new virus. Additionally, the pathophysiology of COVID-19 is highly heterogeneous, and the way of SARS-CoV-2 modulates the different systems in the host remains unidentified, despite recent discoveries. This complex and multifactorial response requires a comprehensive therapeutic approach, enabling the integration and refinement of therapeutic responses of a given single compound that has several action potentials. In this context, natural compounds, such as Curcumin, have shown beneficial effects on the progression of inflammatory diseases due to its numerous action mechanisms: antiviral, anti-inflammatory, anticoagulant, antiplatelet, and cytoprotective. These and many other effects of curcumin make it a promising target in the adjuvant treatment of COVID-19. Hence, the purpose of this review is to specifically point out how curcumin could interfere at different times/points during the infection caused by SARS-CoV-2, providing a substantial contribution of curcumin as a new adjuvant therapy for the treatment of COVID-19.
2019冠状病毒病（COVID-19）是一种迅速在全球传播并导致高死亡率的传染病。尽管了解同一家族病毒引起的既往疾病，如中东呼吸综合征（MERS）和严重急性呼吸综合征冠状病毒（SARS-CoV），但COVID-19患者的管理和治疗仍是一项挑战。全球对抗COVID-19的最佳策略之一是药物重新定位；然而，这些药物并非针对这种新病毒。此外，COVID-19的病理生理学高度异质性，尽管有近期发现，但SARS-CoV-2调节宿主不同系统的方式仍不明。这种复杂的多因素反应需要一种全面的治疗方法，能够整合和优化具有多种作用潜能的单一化合物的治疗反应。在这种背景下，姜黄素等天然化合物因其多种作用机制：抗病毒、抗炎、抗凝、抗血小板和细胞保护，已显示出对炎症性疾病进展的有益作用。姜黄素的这些以及许多其他作用使其成为COVID-19辅助治疗中有前景的靶点。因此，本综述的目的是具体指出姜黄素如何在SARS-CoV-2感染的不同时间/阶段发挥干预作用，为姜黄素作为COVID-19治疗的新辅助疗法提供实质性贡献。
